Increased intratumoral interleukin 22 levels and frequencies of interleukin 22-producing CD4+ T cells correlate with pancreatic cancer progression

Pancreas

Volumn 43, Issue 3, 2014, Pages 470-477

  Xu, Xuejun ^a   Tang, Yichen ^a   Guo, Shixiang ^a   Zhang, Yi ^a   Tian, Yi ^a   Ni, Bing ^a   Wang, Huaizhi ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Pancreatic cancer; STAT 3

Indexed keywords

CYCLIN D1; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 22; PROTEIN BCL 2; STAT3 PROTEIN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ADULT; ARTICLE; CANCER GROWTH; CANCER STAGING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MIDDLE AGED; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; CELL CULTURE; DISEASE COURSE; HELPER CELL; METABOLISM; PATHOLOGY; PHOSPHORYLATION; UPREGULATION;

BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYCLIN D1; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKINS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, HELPER-INDUCER; UP-REGULATION;

EID: 84896688553     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000055     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. Ca Cancer J Clin. 2012;62:10-29.
2. Nitsche C, Simon P, Weiss FU, et al. Environmental risk factors for chronic pancreatitis and pancreatic cancer. Dig Dis. 2011;29:235-242.
3. Dalgleish AG, O'Byrne K. Inflammation and cancer: The role of the immune response and angiogenesis. Cancer Treat Res. 2006;130:1-38.
4. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117:1175-1183.
5. Witte E, Witte K, Warszawska K, et al. Interleukin-22: A cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev. 2010;21:365-379.
6. Wu PW, Li J, Kodangattil SR, et al. IL-22R, IL-10-2, and IL-22BP binding sites are topologically juxtaposed on adjacent and overlapping surfaces of IL-22. J Mol Biol. 2008;382:1168-1183.
7. Radaeva S, Sun R, Pan HN, et al. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology. 2004;39:1332-1342.
8. Sonnenberg GF, Fouser LA, Artis D. Functional biology of the IL-22YIL-22r pathway in regulating immunity and inflammation at barrier surfaces. Adv Immunol. 2010;107:1-29.
9. Nagalakshmi ML, Rascle A, Zurawski S, et al. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacal. 2004;4:679-691.
10. Hoegl S, Bachmann M, Scheiermann P, et al. Protective properties of inhaled IL-22 in a model of ventilator-induced lung injury. Am J Resp Cell Mol. 2011;44:369-376.
11. Shioya M, Andoh A, Kakinoki S, et al. Interleukin 22 receptor 1 expression in pancreas islets. Pancreas. 2008;36:197-199.
12. Lejeune D, Dumoutier L, Constantinescu S, et al. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem. 2002;277:33676-33682.
13. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7:41-51.
14. He G, Karin M. NF-kappab and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011;21:159-168.
15. Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity. 2007;27:647-659.
16. Jiang R, Tan Z, Deng L, et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology. 2011;54:900-909.
17. Trifari S, Spits H. IL-22Yproducing CD4+ T cells: Middle-men between the immune system and its environment. Eur J Immunol. 2010;40:2369-2371.
18. Nograles KE, Zaba LC, Shemer A, et al. IL-22Yproducing ''t22'' T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17Yproducing TH17 T cells. J Allergy Clin Immun. 2009;123:1244-1252 e1242.
19. Fujita H, Nograles KE, Kikuchi T, et al. Human langerhans cells induce distinct IL-22Yproducing CD4+ T cells lacking IL-17 production. P Natl Acan SCI USA. 2009;106:21795-21800.
20. Wolk K, Kunz S, Asadullah K, et al. Cutting edge: Immune cells as sources and targets of the IL-10 family members?. J Immunol. 2002;168:5397-5402.
21. Chung Y, Yang X, Chang SH, et al. Expression and regulation of IL-22 in the IL-17Yproducing CD4+ T lymphocytes. Cell Res. 2006;16:902-907.
22. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a t(h)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648-651.
23. Duhen T, Geiger R, Jarrossay D, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009;10:857-863.
24. Eyerich S, Eyerich K, Pennino D, et al. TH22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119:3573-3585.
25. Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from t(h)-17, t(h)1 and t(h)2 cells. Nat Immunol. 2009;10:864-871.
26. Kagami S, Rizzo HL, Lee JJ, et al. Circulating TH17, TH22, and TH1 cells are increased in psoriasis. J Invest Dermatol. 2010;130:1373-1383.
27. Zhang L, Li JM, Liu XG, et al. Elevated TH22 cells correlated with TH17 cells in patients with rheumatoid arthritis. J Clin Immunol. 2011;31:606-614.
28. Zhuang Y, Peng LS, Zhao YL, et al. Increased intratumoral IL-22Yproducing CD4(+) T cells and TH22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol ImmunI. 2012;61(11):1965-1975.
29. Curd LM, Favors SE, Gregg RK. Pro-Tumour activity of interleukin-22 in hpafii human pancreatic cancer cells. Clin Exp Immunol. 2012;168:192-199.
30. Wolk K, Witte E, Witte K, et al. Biology of interleukin-22. Semin Immunopathol. 2010;32:17-31.
31. Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity. 2004;21:241-254.
32. Lo YH, Torii K, Saito C, et al. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J Dermatol Sci. 2010;58:225-227.
33. Gurney AL. IL-22, a TH1 cytokine that targets the pancreas and select other peripheral tissues. Int Immunopharmacol. 2004;4:669-677.
34. Kreymborg K, Etzensperger R, Dumoutier L, et al. IL-22 is expressed by TH17 cells in an IL-23Ydependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol. 2007;179:8098-8104.
35. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-1617.
36. Egwuagu CE. Stat3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine. 2009;47:149-156.